These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16230216)

  • 1. Efficacy of oral telithromycin in community-acquired pneumonia caused by resistant Streptococcus pneumoniae.
    van Rensburg D; Fogarty C; De Salvo MC; Rangaraju M; Nusrat R
    J Infect; 2005 Oct; 51(3):201-5. PubMed ID: 16230216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of telithromycin in community-acquired pneumonia caused by pneumococci with reduced susceptibility to penicillin and/or erythromycin.
    van Rensburg DJ; Fogarty C; Kohno S; Dunbar L; Rangaraju M; Nusrat R
    Chemotherapy; 2005 Jul; 51(4):186-92. PubMed ID: 15980629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telithromycin in the treatment of pneumococcal community-acquired respiratory tract infections: a review.
    Fogarty CM; Buchanan P; Aubier M; Baz M; van Rensburg D; Rangaraju M; Nusrat R
    Int J Infect Dis; 2006 Mar; 10(2):136-47. PubMed ID: 16183318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
    Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
    J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM; Kohno S; Buchanan P; Aubier M; Baz M
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and bacteriologic efficacy of telithromycin in patients with bacteremic community-acquired pneumonia.
    Carbon C; van Rensburg D; Hagberg L; Fogarty C; Tellier G; Rangaraju M; Nusrat R
    Respir Med; 2006 Apr; 100(4):577-85. PubMed ID: 16376537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
    Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
    J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae.
    Siquier B; Sánchez-Alvarez J; García-Mendez E; Sabriá M; Santos J; Pallarés R; Twynholm M; Dal-Ré R;
    J Antimicrob Chemother; 2006 Mar; 57(3):536-45. PubMed ID: 16446376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.
    Fogarty CM; Patel TC; Dunbar LM; Leroy BP
    BMC Infect Dis; 2005 May; 5():43. PubMed ID: 15927060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic target attainment potential of azithromycin, clarithromycin, and telithromycin in serum and epithelial lining fluid of community-acquired pneumonia patients with penicillin-susceptible, intermediate, and resistant Streptococcus pneumoniae.
    Noreddin AM; El-Khatib WF; Aolie J; Salem AH; Zhanel GG
    Int J Infect Dis; 2009 Jul; 13(4):483-7. PubMed ID: 19046911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacteriological efficacy of 5-day therapy with telithromycin in acute maxillary sinusitis.
    Buchanan P; Roos K; Tellier G; Rangaraju M; Leroy B
    Int J Antimicrob Agents; 2005 Mar; 25(3):237-46. PubMed ID: 15737519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial.
    Fujita J; Niki Y; Kadota J; Yanagihara K; Kaku M; Watanabe A; Aoki N; Hori S; Tanigawara Y; Cash HL; Kohno S
    J Infect Chemother; 2013 Jun; 19(3):472-9. PubMed ID: 23179958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults.
    Pullman J; Champlin J; Vrooman PS
    Int J Clin Pract; 2003 Jun; 57(5):377-84. PubMed ID: 12846341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W; Assawasanti K; Chaimanee P
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model.
    Dandekar PK; Williams P; Tessier PR; Farrell DJ; Nightingale CH; Nicolau DP
    Int J Antimicrob Agents; 2005 Jun; 25(6):530-4. PubMed ID: 15894464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of penicillin resistance on outcome in adult patients with invasive pneumococcal pneumonia: is penicillin useful against intermediately resistant strains?
    Falcó V; Almirante B; Jordano Q; Calonge L; del Valle O; Pigrau C; Planes AM; Gavaldà J; Pahissa A
    J Antimicrob Chemother; 2004 Aug; 54(2):481-8. PubMed ID: 15215226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative development of elevated resistance to macrolides in community-acquired pneumonia caused by Streptococcus pneumoniae.
    Yayan J
    Drug Des Devel Ther; 2014; 8():1733-43. PubMed ID: 25336917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia.
    File TM
    Clin Microbiol Infect; 2006 May; 12 Suppl 3():31-41. PubMed ID: 16669927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.